Skip to main content
NCBI home page
Frontiers in Cellular Neuroscience logoLink to Frontiers in Cellular Neuroscience
. 2016 Mar 29;10:75. doi: 10.3389/fncel.2016.00075

Reelin Proteolysis Affects Signaling Related to Normal Synapse Function and Neurodegeneration

April L Lussier 1, Edwin J Weeber 1, G William Rebeck 2,*
PMCID: PMC4809875  PMID: 27065802

Abstract

Reelin is a neurodevelopmental protein important in adult synaptic plasticity and learning and memory. Recent evidence points to the importance for Reelin proteolysis in normal signaling and in cognitive function. Support for the dysfunction of Reelin proteolysis in neurodegeneration and cognitive dysfunction comes from postmortem analysis of Alzheimer’s diseases (AD) tissues including cerebral spinal fluid (CSF), showing that levels of Reelin fragments are altered in AD compared to control. Potential key proteases involved in Reelin proteolysis have recently been defined, identifying processes that could be altered in neurodegeneration. Introduction of full-length Reelin and its proteolytic fragments into several mouse models of neurodegeneration and neuropsychiatric disorders quickly promote learning and memory. These findings support a role for Reelin in learning and memory and suggest further understanding of these processes are important to harness the potential of this pathway in treating cognitive symptoms in neuropsychiatric and neurodegenerative diseases.

Keywords: Reelin, Alzheimer’s disease, neurodegeneration, proteolysis, learning and memory

Neurodegenerative diseases are characterized by the progressive loss of synapses and neurons, accounting for cognitive deterioration. One molecular pathway that is well characterized in playing a role in adult synaptic plasticity and learning and memory is the Reelin signaling pathway (Weeber et al., 2002; Chen et al., 2005; Qiu et al., 2006a,b; Qiu and Weeber, 2007; Rogers et al., 2011). Reelin is also involved in a number of neurodegenerative and neuropsychiatric disorders presenting with cognitive deficits, including schizophrenia (Guidotti et al., 2000; Chen et al., 2002; Fatemi, 2005; Torrey et al., 2005), bipolar disorder (Fatemi et al., 2000; Torrey et al., 2005), depression (Knable et al., 2004; Lussier et al., 2009, 2011, 2013a,b; Fenton et al., 2015), epilepsy (Fournier et al., 2010; Haas and Frotscher, 2010; Dutta et al., 2011) and autism (Fatemi et al., 2005). Furthermore, Reelin signal transduction pathways appear to be particularly vulnerable in Alzheimer’s disease (AD), potentially contributing to its pathogenesis (Hoe et al., 2006; Hoareau et al., 2008). Thus, a better understanding of Reelin signaling could be useful in developing therapies against synaptic and neuronal loss in a number of conditions.

Reelin in Development

Reelin is an extracellular matrix protein important in brain development during embryogenesis (for detailed reviews, see Lambert de Rouvroit et al., 1999; Rice and Curran, 2001; Tissir and Goffinet, 2003). During development Reelin is expressed by Cajal–Retzius cells in the hippocampus and cortex and granule cells in the cerebellum (Ogawa et al., 1995; Del Río et al., 1997; Frotscher, 1998; Hirota et al., 2015). In the adult brain GABAergic interneurons in the cortex and hippocampus secrete Reelin (Alcantara et al., 1998; Pesold et al., 1998). Much of what we know about the Reelin signaling pathway in development comes from mouse models that have knock-down or overexpression of critical proteins in the pathway: Reelin, lipoprotein receptors, and Disabled-1 (Dab1; Howell et al., 1997b; Hiesberger et al., 1999; Trommsdorff et al., 1999; Beffert et al., 2002; Drakew et al., 2002; Weeber et al., 2002; Qiu et al., 2006a; Pujadas et al., 2010, 2014; Teixeira et al., 2011; Trotter et al., 2013; Lane-Donovan et al., 2015).

Reelin Signaling Pathway

Once Reelin is secreted by GABAergic interneurons into the extracellular space it binds to the lipoprotein receptors, very-low-density lipoprotein receptor (VLDLR) and Apolipoprotein receptor 2 (ApoER2; D’Arcangelo et al., 1999; Weeber et al., 2002; Herz and Chen, 2006; Figure 1). Ligand interactions lead to receptor dimerization and tyrosine phosphorylation of the downstream intracellular adaptor protein Dab1 (Howell et al., 1997a; D’Arcangelo et al., 1999; Hiesberger et al., 1999; Strasser et al., 2004; Herz and Chen, 2006; Trotter et al., 2013, 2014; Divekar et al., 2014). Dab1 phosphorylation activates Src family tyrosine kinases (SFK), such as Fyn, which phosphorylates N-methyl-D-aspartate (NMDA) receptors allowing increases in Ca2+ influx (Chen et al., 2005). Enhancement in Ca2+ influx allows for maturation of NMDA receptors from the NR2B to NR2A receptor subtype, increased membrane α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor insertion, and can contribute to the induction and enhancement of long-term potentiation (LTP; Weeber et al., 2002; Beffert et al., 2005; Chen et al., 2005; Herz and Chen, 2006; Qiu et al., 2006b; Qiu and Weeber, 2007). In addition, Dab1-induced phosphorylation also can activate Phosphatidylinositol-3-kinase (PI3K) and protein kinase B (PKB/Akt) which then causes Glycogen synthase kinase 3 beta (GSK3β) inhibition (Beffert et al., 2002), in turn suppressing tau hyperphosphorylation (Ohkubo et al., 2003).

Figure 1.

Figure 1

Open in a new tab

Reelin signaling pathway in adult synaptic plasticity. Reelin binds to the lipoprotein receptors apolipoprotein receptor 2 (ApoER2) and very-low-density lipoprotein receptor (VLDLR) which causes receptor clustering and the src family tyrosine kinases (SFK) tyrosine phosphorylation of the intracellular adaptor protein Disabled-1 (Dab1), which results in the phosphorylation of N-methyl-D-aspartate receptor (NMDAR; D’Arcangelo et al., 1997, 1999; Weeber et al., 2002; Niu et al., 2004; Beffert et al., 2005; Chen et al., 2005; Qiu et al., 2006b; Qiu and Weeber, 2007; Burrell et al., 2014; Divekar et al., 2014). A subsequent increase in calcium influx leads to depolarization of the post-synaptic membrane and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) insertion (Weeber et al., 2002; Qiu et al., 2006b; Qiu and Weeber, 2007). A consequence of the increase in Ca2+ influx and depolarization of the cell is increased CREB phosphorylation and protein synthesis, which ultimately results in increased synaptic plasticity and learning and memory (Niu et al., 2008; Rogers et al., 2011, 2013). Another result of Dab1 phosphorylation is activation of phosphatidylinositol-3-kinase (PI3K), protein kinase B (PKB/Akt), and modulation of Glycogen synthase kinase 3 beta (GSK3β), which inhibits Tau phosphorylation (Beffert et al., 2002). Phosphorylation of Dab1 also regulates the conversion of p35 to p25 and results in activation of CDK5, also responsible for Tau phosphorylation (Beffert et al., 2004).

As Reelin positive cells are found in highest numbers in the CA1 stratum lacunosum and hilus, they are in prime locations to influence learning and memory, and neurogenesis, respectively. Indeed, Reelin has been shown to enhance synaptic plasticity and learning and memory (Weeber et al., 2002; Herz and Chen, 2006; Rogers and Weeber, 2008), as well as alter migration of adult born neurons (Zhao et al., 2007; Pujadas et al., 2010; Teixeira et al., 2012). In the hippocampus, extracellular Reelin accumulates in the stratum lacunosum (Pesold et al., 1999; Lussier et al., 2009) which makes it in a prime location to influence synaptic activity in the CA1 (Weeber et al., 2002; Herz and Chen, 2006; Rogers and Weeber, 2008). Endogenous cleavage of Reelin in these regions may be used to regulate Reelin’s effects on these processes.

Reelin Processing

Reelin signaling may not be driven by the simple production and release of Reelin from interneurons, as with neuropeptides or small molecule transmitters, but it may be regulated by the directed proteolysis of sequestered, full length, extracellular Reelin. Reelin has been shown to have two main sites of cleavage, between EGF-like repeats 2–3 (R2–3) and repeats 6–7 (R6–7; Jossin et al., 2004; Figure 2). These cleavage sites result in five major fragments that can be found in the adult and developing brain (Jossin et al., 2007; Krstic et al., 2012; Trotter et al., 2014). The middle R3–6 fragment interacts with the VLDLR and ApoER2 and is considered the fragment that is involved in initiating the downstream signaling of the Reelin cascade (Jossin et al., 2004). Our laboratory (Trotter et al., 2014) and others (Nagy et al., 2006; Nogi et al., 2006; Nakano et al., 2007; Hisanaga et al., 2012; Krstic et al., 2012) have attempted to identify Reelin-cleaving enzymes, such as the serine protease tissue plasminogen activator (tPA), matrix metalloproteinases (MMP), and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), and the functional role of this proteolytic processing.

Figure 2.

Figure 2

Open in a new tab

Reelin proteolysis in the adult brain. (A) Full length Reelin is released into the extracellular space by GABAergic interneurons in the adult brain. This full length Reelin is enzymatically cleaved between epidermal growth factor (EGF) repeats 2–3 (R2-R3) and 6–7 (R6-R7; indicated by dotted lines; A,B), by a number of different enzymes. For example, tissue plasminogen activator (tPA), Meprin α and β have been shown to cleave Reelin between R6 and R7 (Kohno et al., 2009; Krstic et al., 2012; Trotter et al., 2014; Sato et al., 2016), while matrix metalloproteinases (MMP)-9 cleaves Reelin between R2 and R3 (Krstic et al., 2012). The ADAMTS 4 and 5 have been shown to cleave Reelin at both sites (Hisanaga et al., 2012; Krstic et al., 2012). Other, yet to be identified proteases, are also potentially involved in Reelin processing. (B) Full length Reelin (450 kDa) is cleaved by a number of enzymes which result in the production of five fragments that range from 370–80 kDa. The R3-R6 fragment [included in the full length Reelin (450 kDa), 370 kDa, 190 kDa, and 270 kDa fragments] has been shown to bind to the lipoprotein receptors, ApoER2 and VLDLR (Jossin et al., 2004). The N-R2 fragment (180 kDa) has been shown to bind to alpha3beta1-integrins (Dulabon et al., 2000) and neuronal migration has been shown to be disrupted in vivo by the CR-50 antibody (Nakajima et al., 1997). The C-terminal region (R7-C; 80 kDa) has been shown to be involved the secretion of Reelin, as well as its proper folding (de Bergeyck et al., 1997; Jossin et al., 2004), and for downstream signaling efficacy (Nakano et al., 2007).

We have recently identified one mechanism for the normal processing of extracellular Reelin, through the effects of the serine protease tPA in the brain (Trotter et al., 2014). The activity-dependent proteolysis of Reelin between R6 and R7 in wild-type mice was not seen in tPA KO mice, supporting a role of this protease in NMDAR-independent LTP induced cleavage of Reelin (Trotter et al., 2014). In cell culture, Reelin cleavage between R6–7 by tPA was blocked by serpin E1 inhibitor (Krstic et al., 2012). Our cell-free conditions in which we incubated tPA with Reelin for 45 min also produced increased the N-R6 fragment (370 kDa), which was blocked with Plasminogen activator inhibitor (PAI-1; serpin E1) and diisoporpyl fluorophosphates (a serine protease inhibitor), but not blocked by Aprotinin or CR-50 (an antibody that binds in the N-terminal region of Reelin; D’Arcangelo et al., 1997; Trotter et al., 2014). Similarly, metalloproteases meprin α and β cleave Reelin between the R6 and R7 repeats (Sato et al., 2016). However, neither tPA knock-out mice (Trotter et al., 2014) nor meprin β knock-out mice (Sato et al., 2016) demonstrate differences in basal levels of full length Reelin or Reelin fragments, suggesting that combinations of proteases are involved in constitutive Reelin levels and proteolysis. Furthermore, Reelin proteolysis may be important in activity-dependent or pathological conditions.

Much of what is known about signaling abilities of specific Reelin domains comes from research on the canonical Reelin-lipoprotein-Dab1 pathway (Figure 1). In support of the importance of the middle R3–6 fragment in lipoprotein receptor binding, cleavage within the R3 repeat has recently been shown to decrease Dab1 phosphorylation (Kohno et al., 2009; Koie et al., 2014). However, the other fragments have also been suggested to be vital for normal Reelin signaling. For example, the N-R2 fragment has been shown to bind to alpha3beta1-integrins (Dulabon et al., 2000) and the CR-50 antibody can disrupt in vivo neuronal migration (Nakajima et al., 1997). The C-terminal region (R7-C) has been suggested to be involved in Reelin secretion, folding (de Bergeyck et al., 1997; Jossin et al., 2004), and signaling efficacy (Nakano et al., 2007), although no known receptors have been identified for R7-C binding. Recently, Kohno et al. (2015), have shown that the C-terminal region is critical in postnatal cerebral cortex development but not in embryonic stages. Further research is needed to fully elucidate the importance of these specific fragments in normal and pathological conditions.

Reelin and Neuropsychiatric/Neurodegenerative Disorders

Support for the role of Reelin proteolysis in human disease has been found in both neuropsychiatric and neurodegenerative disorders. For example, the N-R2 fragment is increased in AD and frontotemporal dementia patients when compared to non-demented patients (Sáez-Valero et al., 2003; Botella-López et al., 2006). In patients with confirmed diagnosis for depression and bipolar disorder, the N-R2 fragment is found to be decreased in blood samples, while for schizophrenia patients the N-R6 fragment is increased (Fatemi et al., 2001). Reelin may also play a role in seizure control: epilepsy models have altered Reelin processing (Tinnes et al., 2011, 2013; Kaneko et al., 2016), which may be MMP-dependent. These differences in Reelin fragment levels point to an importance in Reelin levels and proteolytic dysfunction in disease states.

Reelin and AD Pathoetiology

In AD, loss of synapses and neurons is accompanied neuropathologically by amyloid deposits composed of the Amyloid beta (Aβ) peptide, and neurofibrillary tangles composed of modified versions of the tau protein (Trojanowski and Lee, 2002; Schellenberg and Montine, 2012; Sheng et al., 2012). Exogenous Aβ application and endogenous Aβ aggregates block various forms of synaptic plasticity and inhibit memory formation and retrieval (Klyubin et al., 2005; Selkoe, 2008; Talantova et al., 2013). Hyperphosphorylated forms of tau are also associated with the disruption of synaptic plasticity, learning and memory (Trojanowski and Lee, 2002; Santacruz et al., 2005; Lasagna-Reeves et al., 2011, 2012; Shipton et al., 2011). Altered Reelin signaling has been linked to AD through analyses of human brain samples (Herring et al., 2012; Notter and Knuesel, 2013), and animal models connecting Reelin to the processes of amyloid accumulation (Chin et al., 2007; Kocherhans et al., 2010; Pujadas et al., 2014) and to tau phosphorylation (Ohkubo et al., 2003; Herz and Chen, 2006; Kocherhans et al., 2010; Cuchillo-Ibáñez et al., 2013). In addition, Reelin signaling has been associated with human AD synaptic dysfunction in a non-targeted transcriptomic approach (Karim et al., 2014), and the Reelin gene was associated with AD pathological findings in elderly controls in a non-targeted genomic approach (Kramer et al., 2011). Finally, two of the strongest genetic risk factors for AD, Apolipoprotein E (APOE) and clusterin (APOJ), encode proteins that bind to the Reelin receptors (Reddy et al., 2011; Tapia-González et al., 2011).

These lines of research have led to the investigation of possible mechanisms for how Reelin could specifically affect AD. Reelin may modify amyloid levels by directly interacting with amyloid precursor protein (APP; Hoe et al., 2009) or altering APP metabolism to decrease the generation Aβ (Rice et al., 2013; Pujadas et al., 2014). Reelin also causes GSK3β inhibition (Beffert et al., 2002), which suppresses tau hyperphosphorylation (Ohkubo et al., 2003). In mouse models of AD, overexpressing Reelin prevented AD pathological changes (Pujadas et al., 2014), and lowering levels of Reelin accelerated Aβ deposition and the synaptic dysfunction caused by the presence of amyloid (Kocherhans et al., 2010; Lane-Donovan et al., 2015). In addition to these effects on the neuropathologic accumulations in AD brain, several lines of evidence suggest that Reelin and Aβ have antagonistic effects on neuronal survival and signaling. These findings include reduction of Reelin and Reelin signaling in an AD mouse model (Mota et al., 2014), electrophysiological measures of Reelin and Aβ effects on hippocampal brain slices (Durakoglugil et al., 2009), and behavioral studies in AD mouse models with altered levels of Reelin (Pujadas et al., 2010; Lane-Donovan et al., 2015).

Reelin as a Therapeutic Target

As mentioned above, different Reelin fragments are altered in neuropsychiatric and degenerative diseases. These alterations may be an indication of disruption in Reelin processing and may be useful in identifying biomarkers for disease states. Reelin has been shown to be sequestered by Aβ plaques in an age-dependent manner (Knuesel et al., 2009; Doehner and Knuesel, 2010; Kocherhans et al., 2010; Stranahan et al., 2011). Removal of Reelin from the synapse can alter many Reelin-dependent functions, causing abnormal cellular migration, dendritic morphology atrophy and deficits in synaptic plasticity (Herz and Chen, 2006; Rogers and Weeber, 2008; Bu, 2009). Given the progressive memory decline seen in AD patients, it is possible that the sequestering of Reelin by the amyloid plaques can alter its normal regulation via cleavage mechanisms and its normal enhancement of learning and memory. It is interesting to note that crossing a transgenic mouse that overexpresses Reelin with an AD mouse model protects from amyloid plaque formation and rescues learning and memory deficits when compared to the AD mice (Pujadas et al., 2014), while decreasing Reelin in AD models accelerates plaque formation and increases tau hyperphosphorylation (Kocherhans et al., 2010). Interestingly, a novel inducible Reelin knockout mouse line has revealed that adult knockdown of Reelin expression results in no discernable differences in normal learning and memory and actually enhances late LTP (Lane-Donovan et al., 2015). When these Reelin knockdown mice were crossed with Tg2576 AD mice they did not cause an increase Aβ pathology; however, these mice showed poorer learning in the hidden platform water maze and deficits in the 24 h probe test when compared to controls (Lane-Donovan et al., 2015). These results support the importance of Reelin signaling in normal cognitive function and shows that a loss of Reelin signaling in an AD mouse model increases cognitive dysfunction.

Introduction of exogenous Reelin into the brain can have surprisingly profound effects on synaptic plasticity and cognition. Hippocampal injection(s) of Reelin and its fragments has demonstrated significant improvements in models of Reelin deficiency (Rogers et al., 2013), Angelman syndrome (Hethorn et al., 2015), and schizophrenia (Ishii et al., 2015). Remarkably, exogenous Reelin also enhanced learning and memory as well as increased synaptic plasticity in wild-type mice (Rogers et al., 2011). Thus, therapeutic approaches to promoting Reelin signaling could be useful in protecting synapse function and survival in a range of disorders. This work would require a better understanding of which domains of Reelin are necessary for the regulated Reelin signaling, and assays for examining whether new Reelin-based therapies promote receptor clustering, intracellular signaling, synapse stabilization, and neuronal protection. Although more work is required to fully understand the function of each of these Reelin fragments, the current research points to a therapeutic potential for altering specific Reelin fragments in treating neuronal dysfunction and cognitive deficits in neurodegenerative and neuropsychiatric disorders.

Author Contributions

ALL wrote the review and generated the figures. EJW and GWR edited the content and structure of the review. Each author contributed ideas of topics for inclusion.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This work was supported by R01 AG035379-05 for EJW and GWR.

References

  1. Alcantara S., Ruiz M., D’Arcangelo G., Ezan F., de Lecea L., Curran T., et al. (1998). Regional and cellular patterns of reelin mRNA expression in the forebrain of the developing and adult mouse. J. Neurosci. 18, 7779–7799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beffert U., Morfini G., Bock H. H., Reyna H., Brady S. T., Herz J. (2002). Reelin-mediated signaling locally regulates protein kinase B/Akt and glycogen synthase kinase 3beta. J. Biol. Chem. 277, 49958–49964. 10.1074/jbc.m209205200 [DOI] [PubMed] [Google Scholar]
  3. Beffert U., Weeber E. J., Durudas A., Qiu S., Masiulis I., Sweatt J. D., et al. (2005). Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2. Neuron 47, 567–579. 10.1016/j.neuron.2005.07.007 [DOI] [PubMed] [Google Scholar]
  4. Beffert U., Weeber E. J., Morfini G., Ko J., Brady S. T., Tsai L. H., et al. (2004). Reelin and cyclin-dependent kinase 5-dependent signals cooperate in regulating neuronal migration and synaptic transmission. J. Neurosci. 24, 1897–1906. 10.1523/JNEUROSCI.4084-03.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Botella-López A., Burgaya F., Gavín R., García-Ayllón M. S., Gómez-Tortosa E., Peña-Casanova J., et al. (2006). Reelin expression and glycosylation patterns are altered in Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A 103, 5573–5578. 10.1073/pnas.0601279103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bu G. (2009). Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333–344. 10.1038/nrn2620 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Burrell T. C., Divekar S. D., Weeber E. J., Rebeck G. W. (2014). Fyn tyrosine kinase increases Apolipoprotein E receptor 2 levels and phosphorylation. PLoS One 9:e110845. 10.1371/journal.pone.0110845 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chen Y., Beffert U., Ertunc M., Tang T. S., Kavalali E. T., Bezprozvanny I., et al. (2005). Reelin modulates NMDA receptor activity in cortical neurons. J. Neurosci. 25, 8209–8216. 10.1523/JNEUROSCI.1951-05.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chen M. L., Chen S. Y., Huang C. H., Chen C. H. (2002). Identification of a single nucleotide polymorphism at the 5′ promoter region of human reelin gene and association study with schizophrenia. Mol. Psychiatry 7, 447–448. 10.1038/sj.mp.4001026 [DOI] [PubMed] [Google Scholar]
  10. Chin J., Massaro C. M., Palop J. J., Thwin M. T., Yu G. Q., Bien-Ly N., et al. (2007). Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer’s disease. J. Neurosci. 27, 2727–2733. 10.1523/JNEUROSCI.3758-06.2007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cuchillo-Ibáñez I., Balmaceda V., Botella-López A., Rabano A., Avila J., Sáez-Valero J. (2013). Beta-amyloid impairs reelin signaling. PLoS One 8:e72297. 10.1371/journal.pone.0072297 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. D’Arcangelo G., Homayouni R., Keshvara L., Rice D. S., Sheldon M., Curran T. (1999). Reelin is a ligand for lipoprotein receptors. Neuron 24, 471–479. 10.1016/s0896-6273(00)80860-0 [DOI] [PubMed] [Google Scholar]
  13. D’Arcangelo G., Nakajima K., Miyata T., Ogawa M., Mikoshiba K., Curran T. (1997). Reelin is a secreted glycoprotein recognized by the CR-50 monoclonal antibody. J. Neurosci. 17, 23–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. de Bergeyck V., Nakajima K., Lambert de Rouvroit C., Naerhuyzen B., Goffinet A. M., Miyata T., et al. (1997). A truncated Reelin protein is produced but not secreted in the ’Orleans’ reeler mutation (Reln[rl-Orl]). Brain Res. Mol. Brain Res. 50, 85–90. 10.1016/s0169-328x(97)00166-6 [DOI] [PubMed] [Google Scholar]
  15. Del Río J. A., Heimrich B., Borrell V., Förster E., Drakew A., Alcántara S., et al. (1997). A role for Cajal–Retzius cells and reelin in the development of hippocampal connections. Nature 385, 70–74. 10.1038/385070a0 [DOI] [PubMed] [Google Scholar]
  16. Divekar S. D., Burrell T. C., Lee J. E., Weeber E. J., Rebeck G. W. (2014). Ligand-induced homotypic and heterotypic clustering of Apolipoprotein E receptor 2. J. Biol. Chem. 289, 15894–15903. 10.1074/jbc.M113.537548 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Doehner J., Knuesel I. (2010). Reelin-mediated signaling during normal and pathological forms of aging. Aging Dis. 1, 12–29. [PMC free article] [PubMed] [Google Scholar]
  18. Drakew A., Deller T., Heimrich B., Gebhardt C., Del Turco D., Tielsch A., et al. (2002). Dentate granule cells in reeler mutants and VLDLR and ApoER2 knockout mice. Exp. Neurol. 176, 12–24. 10.1006/exnr.2002.7918 [DOI] [PubMed] [Google Scholar]
  19. Dulabon L., Olson E. C., Taglienti M. G., Eisenhuth S., McGrath B., Walsh C. A., et al. (2000). Reelin binds alpha3beta1 integrin and inhibits neuronal migration. Neuron 27, 33–44. 10.1016/s0896-6273(00)00007-6 [DOI] [PubMed] [Google Scholar]
  20. Durakoglugil M. S., Chen Y., White C. L., Kavalali E. T., Herz J. (2009). Reelin signaling antagonizes β-amyloid at the synapse. Proc. Natl. Acad. Sci. U S A 106, 15938–15943. 10.1073/pnas.0908176106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Dutta S., Gangopadhyay P. K., Sinha S., Chatterjee A., Ghosh S., Rajamma U. (2011). An association analysis of Reelin gene (RELN) polymorphisms with childhood epilepsy in eastern Indian population from West Bengal. Cell. Mol. Neurobiol. 31, 45–56. 10.1007/s10571-010-9551-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Fatemi S. H. (2005). Reelin glycoprotein in autism and schizophrenia. Int. Rev. Neurobiol. 71, 179–187. 10.1016/s0074-7742(05)71008-4 [DOI] [PubMed] [Google Scholar]
  23. Fatemi S. H., Earle J. A., McMenomy T. (2000). Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol. Psychiatry 5, 654–663, 571. 10.1038/sj.mp.4000783 [DOI] [PubMed] [Google Scholar]
  24. Fatemi S. H., Kroll J. L., Stary J. M. (2001). Altered levels of Reelin and its isoforms in schizophrenia and mood disorders. Neuroreport 12, 3209–3215. 10.1097/00001756-200110290-00014 [DOI] [PubMed] [Google Scholar]
  25. Fatemi S. H., Snow A. V., Stary J. M., Araghi-Niknam M., Reutiman T. J., Lee S., et al. (2005). Reelin signaling is impaired in autism. Biol. Psychiatry 57, 777–787. 10.1016/j.biopsych.2004.12.018 [DOI] [PubMed] [Google Scholar]
  26. Fenton E. Y., Fournier N. M., Lussier A. L., Romay-Tallon R., Caruncho H. J., Kalynchuk L. E. (2015). Imipramine protects against the deleterious effects of chronic corticosterone on depression-like behavior, hippocampal reelin expression and neuronal maturation. Prog. Neuropsychopharmacol. Biol. Psychiatry 60, 52–59. 10.1016/j.pnpbp.2015.02.001 [DOI] [PubMed] [Google Scholar]
  27. Fournier N. M., Andersen D. R., Botterill J. J., Sterner E. Y., Lussier A. L., Caruncho H. J., et al. (2010). The effect of amygdala kindling on hippocampal neurogenesis coincides with decreased reelin and DISC1 expression in the adult dentate gyrus. Hippocampus 20, 659–671. 10.1002/hipo.20653 [DOI] [PubMed] [Google Scholar]
  28. Frotscher M. (1998). Cajal–Retzius cells, Reelin and the formation of layers. Curr. Opin. Neurobiol. 8, 570–575. 10.1016/s0959-4388(98)80082-2 [DOI] [PubMed] [Google Scholar]
  29. Guidotti A., Auta J., Davis J. M., Di-Giorgi-Gerevini V., Dwivedi Y., Grayson D. R., et al. (2000). Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry 57, 1061–1069. 10.1001/archpsyc.57.11.1061 [DOI] [PubMed] [Google Scholar]
  30. Haas C. A., Frotscher M. (2010). Reelin deficiency causes granule cell dispersion in epilepsy. Exp. Brain Res. 200, 141–149. 10.1007/s00221-009-1948-5 [DOI] [PubMed] [Google Scholar]
  31. Herring A., Donath A., Steiner K. M., Widera M. P., Hamzehian S., Kanakis D., et al. (2012). Reelin depletion is an early phenomenon of Alzheimer’s pathology. J. Alzheimers Dis. 30, 963–979. 10.3233/JAD-2012-112069 [DOI] [PubMed] [Google Scholar]
  32. Herz J., Chen Y. (2006). Reelin, lipoprotein receptors and synaptic plasticity. Nat. Rev. Neurosci. 7, 850–859. 10.1038/nrn2009 [DOI] [PubMed] [Google Scholar]
  33. Hethorn W. R., Ciarlone S. L., Filonova I., Rogers J. T., Aguirre D., Ramirez R. A., et al. (2015). Reelin supplementation recovers synaptic plasticity and cognitive deficits in a mouse model for Angelman syndrome. Eur. J. Neurosci. 41, 1372–1380. 10.1111/ejn.12893 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Hiesberger T., Trommsdorff M., Howell B. W., Goffinet A., Mumby M. C., Cooper J. A., et al. (1999). Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron 24, 481–489. 10.1016/s0896-6273(00)80861-2 [DOI] [PubMed] [Google Scholar]
  35. Hirota Y., Kubo K., Katayama K., Honda T., Fujino T., Yamamoto T. T., et al. (2015). Reelin receptors ApoER2 and VLDLR are expressed in distinct spatiotemporal patterns in developing mouse cerebral cortex. J. Comp. Neurol. 523, 463–478. 10.1002/cne.23691 [DOI] [PubMed] [Google Scholar]
  36. Hisanaga A., Morishita S., Suzuki K., Sasaki K., Koie M., Kohno T., et al. (2012). A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS-4) cleaves Reelin in an isoform-dependent manner. FEBS Lett. 586, 3349–3353. 10.1016/j.febslet.2012.07.017 [DOI] [PubMed] [Google Scholar]
  37. Hoareau C., Borrell V., Soriano E., Krebs M. O., Prochiantz A., Allinquant B. (2008). Amyloid precursor protein cytoplasmic domain antagonizes Reelin neurite outgrowth inhibition of hippocampal neurons. Neurobiol. Aging 29, 542–553. 10.1016/j.neurobiolaging.2006.11.012 [DOI] [PubMed] [Google Scholar]
  38. Hoe H. S., Lee K. J., Carney R. S., Lee J., Markova A., Lee J. Y., et al. (2009). Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. J. Neurosci. 29, 7459–7473. 10.1523/JNEUROSCI.4872-08.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Hoe H. S., Tran T. S., Matsuoka Y., Howell B. W., Rebeck G. W. (2006). DAB1 and Reelin effects on amyloid precursor protein and ApoE receptor 2 trafficking and processing. J. Biol. Chem. 281, 35176–35185. 10.1074/jbc.m602162200 [DOI] [PubMed] [Google Scholar]
  40. Howell B. W., Gertler F. B., Cooper J. A. (1997a). Mouse disabled (mDab1): a Src binding protein implicated in neuronal development. EMBO J. 16, 121–132. 10.1093/emboj/16.1.121 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Howell B. W., Hawkes R., Soriano P., Cooper J. A. (1997b). Neuronal position in the developing brain is regulated by mouse disabled-1. Nature 389, 733–737. 10.1038/39607 [DOI] [PubMed] [Google Scholar]
  42. Ishii K., Nagai T., Hirota Y., Noda M., Nabeshima T., Yamada K., et al. (2015). Reelin has a preventive effect on phencyclidine-induced cognitive and sensory-motor gating deficits. Neurosci. Res. 96, 30–36. 10.1016/j.neures.2014.12.013 [DOI] [PubMed] [Google Scholar]
  43. Jossin Y., Gui L., Goffinet A. M. (2007). Processing of Reelin by embryonic neurons is important for function in tissue but not in dissociated cultured neurons. J. Neurosci. 27, 4243–4252. 10.1523/jneurosci.0023-07.2007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Jossin Y., Ignatova N., Hiesberger T., Herz J., Lambert de Rouvroit C., Goffinet A. M. (2004). The central fragment of Reelin, generated by proteolytic processing in vivo, is critical to its function during cortical plate development. J. Neurosci. 24, 514–521. 10.1523/jneurosci.3408-03.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Kaneko Y., Sullivan R., Dailey T., Vale F. L., Tajiri N., Borlongan C. V. (2016). Kainic acid-induced golgi complex fragmentation/dispersal shifts the proteolysis of reelin in primary rat neuronal cells: an in vitro model of early stage epilepsy. Mol. Neurobiol. 53, 1874–1883. 10.1007/s12035-015-9126-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Karim S., Mirza Z., Ansari S. A., Rasool M., Iqbal Z., Sohrab S. S., et al. (2014). Transcriptomics study of neurodegenerative disease: emphasis on synaptic dysfunction mechanism in Alzheimer’s disease. CNS Neurol. Disord. Drug Targets 13, 1202–1212. 10.2174/1871527313666140917113446 [DOI] [PubMed] [Google Scholar]
  47. Klyubin I., Walsh D. M., Lemere C. A., Cullen W. K., Shankar G. M., Betts V., et al. (2005). Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11, 556–561. 10.1038/nm1234 [DOI] [PubMed] [Google Scholar]
  48. Knable M. B., Barci B. M., Webster M. J., Meador-Woodruff J., Torrey E. F., Stanley Neuropathology C. (2004). Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the stanley neuropathology consortium. Mol. Psychiatry 9, 609–620, 544. 10.1038/sj.mp.4001471 [DOI] [PubMed] [Google Scholar]
  49. Knuesel I., Nyffeler M., Mormède C., Muhia M., Meyer U., Pietropaolo S., et al. (2009). Age-related accumulation of Reelin in amyloid-like deposits. Neurobiol. Aging 30, 697–716. 10.1016/j.neurobiolaging.2007.08.011 [DOI] [PubMed] [Google Scholar]
  50. Kocherhans S., Madhusudan A., Doehner J., Breu K. S., Nitsch R. M., Fritschy J. M., et al. (2010). Reduced Reelin expression accelerates amyloid-β plaque formation and tau pathology in transgenic Alzheimer’s disease mice. J. Neurosci. 30, 9228–9240. 10.1523/JNEUROSCI.0418-10.2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Kohno T., Honda T., Kubo K., Nakano Y., Tsuchiya A., Murakami T., et al. (2015). Importance of Reelin C-terminal region in the development and maintenance of the postnatal cerebral cortex and its regulation by specific proteolysis. J. Neurosci. 35, 4776–4787. 10.1523/JNEUROSCI.4119-14.2015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Kohno S., Kohno T., Nakano Y., Suzuki K., Ishii M., Tagami H., et al. (2009). Mechanism and significance of specific proteolytic cleavage of Reelin. Biochem. Biophys. Res. Commun. 380, 93–97. 10.1016/j.bbrc.2009.01.039 [DOI] [PubMed] [Google Scholar]
  53. Koie M., Okumura K., Hisanaga A., Kamei T., Sasaki K., Deng M., et al. (2014). Cleavage within Reelin repeat 3 regulates the duration and range of signaling activity of Reelin. J. Biol. Chem. 289, 12922–12930. 10.1074/jbc.M113.536326 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Kramer P. L., Xu H., Woltjer R. L., Westaway S. K., Clark D., Erten-Lyons D., et al. (2011). Alzheimer’s disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol. Aging 32, 2113–2122. 10.1016/j.neurobiolaging.2010.01.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Krstic D., Rodriguez M., Knuesel I. (2012). Regulated proteolytic processing of Reelin through interplay of tissue plasminogen activator (tPA), ADAMTS-4, ADAMTS-5 and their modulators. PLoS One 7:e47793. 10.1371/journal.pone.0047793 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Lambert de Rouvroit C., de Bergeyck V., Cortvrindt C., Bar I., Eeckhout Y., Goffinet A. M. (1999). Reelin, the extracellular matrix protein deficient in reeler mutant mice, is processed by a metalloproteinase. Exp. Neurol. 156, 214–217. 10.1006/exnr.1998.7007 [DOI] [PubMed] [Google Scholar]
  57. Lane-Donovan C., Philips G. T., Wasser C. R., Durakoglugil M. S., Masiulis I., Upadhaya A., et al. (2015). Reelin protects against amyloid β toxicity in vivo. Sci. Signal. 8:ra67. 10.1126/scisignal.aaa6674 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Lasagna-Reeves C. A., Castillo-Carranza D. L., Sengupta U., Clos A. L., Jackson G. R., Kayed R. (2011). Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol. Neurodegener. 6:39. 10.1186/1750-1326-6-39 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Lasagna-Reeves C. A., Castillo-Carranza D. L., Sengupta U., Guerrero-Munoz M. J., Kiritoshi T., Neugebauer V., et al. (2012). Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2:700. 10.1038/srep00700 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Lussier A. L., Caruncho H. J., Kalynchuk L. E. (2009). Repeated exposure to corticosterone, but not restraint, decreases the number of Reelin-positive cells in the adult rat hippocampus. Neurosci. Lett. 460, 170–174. 10.1016/j.neulet.2009.05.050 [DOI] [PubMed] [Google Scholar]
  61. Lussier A. L., Lebedeva K., Fenton E. Y., Guskjolen A., Caruncho H. J., Kalynchuk L. E. (2013a). The progressive development of depression-like behavior in corticosterone-treated rats is paralleled by slowed granule cell maturation and decreased reelin expression in the adult dentate gyrus. Neuropharmacology 71C, 174–183. 10.1016/j.neuropharm.2013.04.012 [DOI] [PubMed] [Google Scholar]
  62. Lussier A. L., Romay-Tallón R., Caruncho H. J., Kalynchuk L. E. (2013b). Altered GABAergic and glutamatergic activity within the rat hippocampus and amygdala in rats subjected to repeated corticosterone administration but not restraint stress. Neuroscience 231, 38–48. 10.1016/j.neuroscience.2012.11.037 [DOI] [PubMed] [Google Scholar]
  63. Lussier A. L., Romay-Tallon R., Kalynchuk L. E., Caruncho H. J. (2011). Reelin as a putative vulnerability factor for depression: examining the depressogenic effects of repeated corticosterone in heterozygous reeler mice. Neuropharmacology 60, 1064–1074. 10.1016/j.neuropharm.2010.09.007 [DOI] [PubMed] [Google Scholar]
  64. Mota S. I., Ferreira I. L., Valero J., Ferreiro E., Carvalho A. L., Oliveira C. R., et al. (2014). Impaired Src signaling and post-synaptic actin polymerization in Alzheimer’s disease mice hippocampus-linking NMDA receptors and the reelin pathway. Exp. Neurol. 261, 698–709. 10.1016/j.expneurol.2014.07.023 [DOI] [PubMed] [Google Scholar]
  65. Nagy V., Bozdagi O., Matynia A., Balcerzyk M., Okulski P., Dzwonek J., et al. (2006). Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J. Neurosci. 26, 1923–1934. 10.1523/jneurosci.4359-05.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Nakajima K., Mikoshiba K., Miyata T., Kudo C., Ogawa M. (1997). Disruption of hippocampal development in vivo by CR-50 mAb against reelin. Proc. Natl. Acad. Sci. U S A 94, 8196–8201. 10.1073/pnas.94.15.8196 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Nakano Y., Kohno T., Hibi T., Kohno S., Baba A., Mikoshiba K., et al. (2007). The extremely conserved C-terminal region of Reelin is not necessary for secretion but is required for efficient activation of downstream signaling. J. Biol. Chem. 282, 20544–20552. 10.1074/jbc.m702300200 [DOI] [PubMed] [Google Scholar]
  68. Niu S., Renfro A., Quattrocchi C. C., Sheldon M., D’Arcangelo G. (2004). Reelin promotes hippocampal dendrite development through the VLDLR/ApoER2-Dab1 pathway. Neuron 41, 71–84. 10.1016/s0896-6273(03)00819-5 [DOI] [PubMed] [Google Scholar]
  69. Niu S., Yabut O., D’Arcangelo G. (2008). The Reelin signaling pathway promotes dendritic spine development in hippocampal neurons. J. Neurosci. 28, 10339–10348. 10.1523/JNEUROSCI.1917-08.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Nogi T., Yasui N., Hattori M., Iwasaki K., Takagi J. (2006). Structure of a signaling-competent reelin fragment revealed by X-ray crystallography and electron tomography. EMBO J. 25, 3675–3683. 10.1038/sj.emboj.7601240 [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Notter T., Knuesel I. (2013). Reelin immunoreactivity in neuritic varicosities in the human hippocampal formation of non-demented subjects and Alzheimer’s disease patients. Acta Neuropathol. Commun. 1:27. 10.1186/2051-5960-1-27 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Ogawa M., Miyata T., Nakajima K., Yagyu K., Seike M., Ikenaka K., et al. (1995). The reeler gene-associated antigen on Cajal–Retzius neurons is a crucial molecule for laminar organization of cortical neurons. Neuron 14, 899–912. 10.1016/0896-6273(95)90329-1 [DOI] [PubMed] [Google Scholar]
  73. Ohkubo N., Lee Y. D., Morishima A., Terashima T., Kikkawa S., Tohyama M., et al. (2003). Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an Apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3beta cascade. FASEB J. 17, 295–297. 10.1096/fj.02-0434fje [DOI] [PubMed] [Google Scholar]
  74. Pesold C., Impagnatiello F., Pisu M. G., Uzunov D. P., Costa E., Guidotti A., et al. (1998). Reelin is preferentially expressed in neurons synthesizing gamma-aminobutyric acid in cortex and hippocampus of adult rats. Proc. Natl. Acad. Sci. U S A 95, 3221–3226. 10.1073/pnas.95.6.3221 [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Pesold C., Liu W. S., Guidotti A., Costa E., Caruncho H. J. (1999). Cortical bitufted, horizontal and Martinotti cells preferentially express and secrete Reelin into perineuronal nets, nonsynaptically modulating gene expression. Proc. Natl. Acad. Sci. U S A 96, 3217–3222. 10.1073/pnas.96.6.3217 [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Pujadas L., Gruart A., Bosch C., Delgado L., Teixeira C. M., Rossi D., et al. (2010). Reelin regulates postnatal neurogenesis and enhances spine hypertrophy and long-term potentiation. J. Neurosci. 30, 4636–4649. 10.1523/JNEUROSCI.5284-09.2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Pujadas L., Rossi D., Andres R., Teixeira C. M., Serra-Vidal B., Parcerisas A., et al. (2014). Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer’s disease. Nat. Commun. 5:3443. 10.1038/ncomms4443 [DOI] [PubMed] [Google Scholar]
  78. Qiu S., Korwek K. M., Pratt-Davis A. R., Peters M., Bergman M. Y., Weeber E. J. (2006a). Cognitive disruption and altered hippocampus synaptic function in Reelin haploinsufficient mice. Neurobiol. Learn. Mem. 85, 228–242. 10.1016/j.nlm.2005.11.001 [DOI] [PubMed] [Google Scholar]
  79. Qiu S., Zhao L. F., Korwek K. M., Weeber E. J. (2006b). Differential reelin-induced enhancement of NMDA and AMPA receptor activity in the adult hippocampus. J. Neurosci. 26, 12943–12955. 10.1523/jneurosci.2561-06.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Qiu S., Weeber E. J. (2007). Reelin signaling facilitates maturation of CA1 glutamatergic synapses. J. Neurophysiol. 97, 2312–2321. 10.1152/jn.00869.2006 [DOI] [PubMed] [Google Scholar]
  81. Reddy S. S., Connor T. E., Weeber E. J., Rebeck W. (2011). Similarities and differences in structure, expression and functions of VLDLR and ApoER2. Mol. Neurodegener. 6:30. 10.1186/1750-1326-6-30 [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Rice D. S., Curran T. (2001). Role of the reelin signaling pathway in central nervous system development. Annu. Rev. Neurosci. 24, 1005–1039. 10.1146/annurev.neuro.24.1.1005 [DOI] [PubMed] [Google Scholar]
  83. Rice H. C., Young-Pearse T. L., Selkoe D. J. (2013). Systematic evaluation of candidate ligands regulating ectodomain shedding of amyloid precursor protein. Biochemistry 52, 3264–3277. 10.1021/bi400165f [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Rogers J. T., Rusiana I., Trotter J., Zhao L., Donaldson E., Pak D. T., et al. (2011). Reelin supplementation enhances cognitive ability, synaptic plasticity and dendritic spine density. Learn. Mem. 18, 558–564. 10.1101/lm.2153511 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Rogers J. T., Weeber E. J. (2008). Reelin and ApoE actions on signal transduction, synaptic function and memory formation. Neuron Glia Biol. 4, 259–270. 10.1017/s1740925x09990184 [DOI] [PubMed] [Google Scholar]
  86. Rogers J. T., Zhao L., Trotter J. H., Rusiana I., Peters M. M., Li Q., et al. (2013). Reelin supplementation recovers sensorimotor gating, synaptic plasticity and associative learning deficits in the heterozygous reeler mouse. J. Psychopharmacol. 27, 386–395. 10.1177/0269881112463468 [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Sáez-Valero J., Costell M., Sjögren M., Andreasen N., Blennow K., Luque J. M. (2003). Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer’s disease. J. Neurosci. Res. 72, 132–136. 10.1002/jnr.10554 [DOI] [PubMed] [Google Scholar]
  88. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., et al. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476–481. 10.1126/science.1113694 [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Sato Y., Kobayashi D., Kohno T., Kidani Y., Prox J., Becker-Pauly C., et al. (2016). Determination of cleavage site of Reelin between its sixth and seventh repeat and contribution of meprin metalloproteases to the cleavage. J. Biochem. 159, 305–312. 10.1093/jb/mvv102 [DOI] [PubMed] [Google Scholar]
  90. Schellenberg G. D., Montine T. J. (2012). The genetics and neuropathology of Alzheimer’s disease. Acta Neuropathol. 124, 305–323. 10.1007/s00401-012-0996-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Selkoe D. J. (2008). Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106–113. 10.1016/j.bbr.2008.02.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Sheng M., Sabatini B. L., Südhof T. C. (2012). Synapses and Alzheimer’s disease. Cold Spring Harb. Perspect. Biol. 4:a005777. 10.1101/cshperspect.a005777 [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Shipton O. A., Leitz J. R., Dworzak J., Acton C. E., Tunbridge E. M., Denk F., et al. (2011). Tau protein is required for amyloid β-induced impairment of hippocampal long-term potentiation. J. Neurosci. 31, 1688–1692. 10.1523/JNEUROSCI.2610-10.2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Stranahan A. M., Haberman R. P., Gallagher M. (2011). Cognitive decline is associated with reduced reelin expression in the entorhinal cortex of aged rats. Cereb. Cortex 21, 392–400. 10.1093/cercor/bhQ116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Strasser V., Fasching D., Hauser C., Mayer H., Bock H. H., Hiesberger T., et al. (2004). Receptor clustering is involved in Reelin signaling. Mol. Cell. Biol. 24, 1378–1386. 10.1128/mcb.24.3.1378-1386.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Talantova M., Sanz-Blasco S., Zhang X., Xia P., Akhtar M. W., Okamoto S., et al. (2013). Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation and synaptic loss. Proc. Natl. Acad. Sci. U S A 110, E2518–E2527. 10.1073/pnas.1306832110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Tapia-González S., García-Segura L. M., Tena-Sempere M., Frago L. M., Castellano J. M., Fuente-Martin E., et al. (2011). Activation of microglia in specific hypothalamic nuclei and the cerebellum of adult rats exposed to neonatal overnutrition. J. Neuroendocrinol. 23, 365–370. 10.1111/j.1365-2826.2011.02113.x [DOI] [PubMed] [Google Scholar]
  98. Teixeira C. M., Kron M. M., Masachs N., Zhang H., Lagace D. C., Martinez A., et al. (2012). Cell-autonomous inactivation of the Reelin pathway impairs adult neurogenesis in the hippocampus. J. Neurosci. 32, 12051–12065. 10.1523/jneurosci.1857-12.2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Teixeira C. M., Martin E. D., Sahun I., Masachs N., Pujadas L., Corvelo A., et al. (2011). Overexpression of Reelin prevents the manifestation of behavioral phenotypes related to schizophrenia and bipolar disorder. Neuropsychopharmacology 36, 2395–2405. 10.1038/npp.2011.153 [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Tinnes S., Ringwald J., Haas C. A. (2013). TIMP-1 inhibits the proteolytic processing of Reelin in experimental epilepsy. FASEB J. 27, 2542–2552. 10.1096/fj.12-224899 [DOI] [PubMed] [Google Scholar]
  101. Tinnes S., Schäfer M. K., Flubacher A., Munzner G., Frotscher M., Haas C. A. (2011). Epileptiform activity interferes with proteolytic processing of Reelin required for dentate granule cell positioning. FASEB J. 25, 1002–1013. 10.1096/fj.10-168294 [DOI] [PubMed] [Google Scholar]
  102. Tissir F., Goffinet A. M. (2003). Reelin and brain development. Nat. Rev. Neurosci. 4, 496–505. 10.1038/nrn1113 [DOI] [PubMed] [Google Scholar]
  103. Torrey E. F., Barci B. M., Webster M. J., Bartko J. J., Meador-Woodruff J. H., Knable M. B. (2005). Neurochemical markers for schizophrenia, bipolar disorder and major depression in postmortem brains. Biol. Psychiatry 57, 252–260. 10.1016/j.biopsych.2004.10.019 [DOI] [PubMed] [Google Scholar]
  104. Trojanowski J. Q., Lee V. M. (2002). The role of tau in Alzheimer’s disease. Med. Clin. North Am. 86, 615–627. 10.1016/S0025-7125(02)00002-0 [DOI] [PubMed] [Google Scholar]
  105. Trommsdorff M., Gotthardt M., Hiesberger T., Shelton J., Stockinger W., Nimpf J., et al. (1999). Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 97, 689–701. 10.1016/s0092-8674(00)80782-5 [DOI] [PubMed] [Google Scholar]
  106. Trotter J., Lee G. H., Kazdoba T. M., Crowell B., Domogauer J., Mahoney H. M., et al. (2013). Dab1 is required for synaptic plasticity and associative learning. J. Neurosci. 33, 15652–15668. 10.1523/JNEUROSCI.2010-13.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Trotter J. H., Lussier A. L., Psilos K. E., Mahoney H. L., Sponaugle A. E., Hoe H. S., et al. (2014). Extracellular proteolysis of reelin by tissue plasminogen activator following synaptic potentiation. Neuroscience 274, 299–307. 10.1016/j.neuroscience.2014.05.046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Weeber E. J., Beffert U., Jones C., Christian J. M., Forster E., Sweatt J. D., et al. (2002). Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J. Biol. Chem. 277, 39944–39952. 10.1074/jbc.m205147200 [DOI] [PubMed] [Google Scholar]
  109. Zhao S., Chai X., Frotscher M. (2007). Balance between neurogenesis and gliogenesis in the adult hippocampus: role for Reelin. Dev. Neurosci. 29, 84–90. 10.1159/000096213 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Cellular Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES